Palvella Therapeutics宣布将举办专题电话会议,重点解读其候选药物Qtorin™ 3.9%雷帕霉素无水凝胶(Qtorin™ Rapamycin)针对微囊型淋巴管畸形适应症的三期Selva临床试验的顶线结果。此次会议将深入探讨该试验的核心数据及其潜在临床价值。
Palvella Therapeutics宣布将举办专题电话会议,重点解读其候选药物Qtorin™ 3.9%雷帕霉素无水凝胶(Qtorin™ Rapamycin)针对微囊型淋巴管畸形适应症的三期Selva临床试验的顶线结果。此次会议将深入探讨该试验的核心数据及其潜在临床价值。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.